GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Common Stock

Arovella Therapeutics (ASX:ALA) Common Stock : A$105.63 Mil (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Common Stock?

Arovella Therapeutics's quarterly common stock increased from Dec. 2023 (A$91.78 Mil) to Jun. 2024 (A$104.30 Mil) and increased from Jun. 2024 (A$104.30 Mil) to Dec. 2024 (A$105.63 Mil).

Arovella Therapeutics's annual common stock increased from Jun. 2022 (A$83.54 Mil) to Jun. 2023 (A$88.87 Mil) and increased from Jun. 2023 (A$88.87 Mil) to Jun. 2024 (A$104.30 Mil).


Arovella Therapeutics Common Stock Historical Data

The historical data trend for Arovella Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Common Stock Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.39 77.00 83.54 88.87 104.30

Arovella Therapeutics Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.64 88.87 91.78 104.30 105.63

Arovella Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Arovella Therapeutics Business Description

Traded in Other Exchanges
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines